

# PRODUCT INFORMATION




## Flucloxacillin (sodium salt)

Item No. 35241

**CAS Registry No.:** 1847-24-1  
**Formal Name:** (2S,5R,6R)-6-[[[3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl]carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, monosodium salt

**Synonym:** NSC 277175  
**MF:** C<sub>19</sub>H<sub>16</sub>ClFN<sub>3</sub>O<sub>5</sub>S • Na  
**FW:** 475.9  
**Purity:** ≥90%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Flucloxacillin (sodium salt) is supplied as a solid. A stock solution may be made by dissolving the flucloxacillin (sodium salt) in the solvent of choice, which should be purged with an inert gas. Flucloxacillin (sodium salt) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of flucloxacillin (sodium salt) in these solvents is approximately 2, 5, and 10 mg/ml, respectively.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of flucloxacillin (sodium salt) can be prepared by directly dissolving the solid in aqueous buffers. The solubility of flucloxacillin (sodium salt) in PBS (pH 7.2) is approximately 5 mg/ml. We do not recommend storing the aqueous solution for more than one day.

### Description

Flucloxacillin is a  $\beta$ -lactam antibiotic.<sup>1</sup> It is active against clinical isolates of *S. aureus* (MICs = 0.12-0.25 mg/L). Flucloxacillin (42.3 mg/kg every six hours) decreases vegetation titers in a rat model of aortic valve endocarditis induced by *S. aureus*. Formulations containing flucloxacillin have been used in the treatment of bacterial infections.

### Reference

- Entenza, J.M., Vouillamoz, J., Glauser, M.P., *et al.* Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **41(8)**, 1662-1667 (1997).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/12/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM